Gómez-Huelgas Ricardo, Martínez-Sellés Manuel, Formiga Francesc, Alemán Sánchez José Juan, Camafort Miguel, Galve Enrique, Gil Pedro, Lobos José María
Sociedad Española de Medicina Interna (SEMI), España.
Sociedad Española de Cardiología (SEC), España.
Med Clin (Barc). 2014 Aug 4;143(3):134.e1-11. doi: 10.1016/j.medcli.2014.04.001. Epub 2014 Jun 5.
The number of patients older than 80 years is steadily increasing and it represents the main basis for increasing population figures in developed countries. Cardiovascular diseases are the leading causes of mortality and disability causes result in a huge burden of disease in elderly people. However, available scientific evidence to support decision-making on cardiovascular prevention in elderly patients is scarce. Currently available risk assessment scales cannot be applied to elderly people. They are focused on cardiovascular mortality risk and do not provide information on factors with a proven prognostic value in the very old (functioning disability, dementia). Elderly people are a highly heterogeneous population, with a variety of co-morbidities, as well as several functional and cognitive impairment degrees. Furthermore, aging-associated physiological changes and common use of multiple drugs result in an increased risk of adverse drug reactions. Thus, drug use should always be based on a risk/benefit assessment in the elderly. Therefore, therapeutic decision-making in the very old must be an individually tailored and based on an appropriate clinical judgement and a comprehensive geriatric assessment. The current consensus report aims to present a proposal for clinical practices in the primary and secondary cardiovascular prevention in the very old and to provide a number of recommendations on lifestyle changes and drug therapy for the management of major cardiovascular risk factors.
80岁以上患者的数量在稳步增加,这是发达国家人口增长的主要原因。心血管疾病是导致老年人死亡和残疾的主要原因,给老年人带来了巨大的疾病负担。然而,支持老年患者心血管疾病预防决策的科学证据却很匮乏。目前可用的风险评估量表不适用于老年人。这些量表侧重于心血管疾病死亡风险,并未提供关于在高龄老人(功能残疾、痴呆)中具有已证实预后价值的因素的信息。老年人是一个高度异质的群体,存在多种合并症以及不同程度的功能和认知障碍。此外,与衰老相关的生理变化和多种药物的常用导致药物不良反应风险增加。因此,老年人用药应始终基于风险/效益评估。所以,高龄老人的治疗决策必须是个体化定制的,基于适当的临床判断和全面的老年医学评估。当前的共识报告旨在提出一份关于高龄老人一级和二级心血管疾病预防临床实践的建议,并就主要心血管危险因素管理的生活方式改变和药物治疗提供一些建议。